Inulin
Inulin, chicory-derived fructan and soluble fibre
Written by Aaron CuhaReviewed Sep 2026
Also known as: Chicory root fibre, Inulin-type fructans, Oligofructose
No lifespan benefit in either sex in the mouse cohort where glycine produced a 4 to 6 percent gain. In 33 human trials of 1,346 people it lowered HbA1c by 0.58 percentage points in prediabetes and type 2 diabetes.
Overview
Inulin is a soluble fibre from chicory root that reaches the colon undigested and is fermented by resident bacteria, which is the basis of both its prebiotic claims and its reputation for causing wind.
It was tested by the Interventions Testing Program in the cohort that produced the glycine result. Elevated dietary glycine extended lifespan by 4 to 6 percent in both sexes with a significant increase in maximum lifespan. In parallel analyses of the same cohort, the authors report no benefit from inulin, from the PAI-1 inhibitor TM5441, or from aspirin at either of two doses.
That null sits alongside a reasonable human literature, none of which is about lifespan. A meta-analysis of 33 randomised trials in 1,346 participants found inulin-type fructans reduced fasting blood glucose by 0.60 mmol/L and HbA1c by 0.58 percentage points in people with prediabetes or type 2 diabetes, with the authors rating the evidence for those two outcomes as high quality and the insulin outcomes as low. A four-week crossover trial in 39 people with functional constipation found 12 g of chicory inulin daily improved stool frequency and constipation-related quality of life, with a carry-over effect that complicated the crossover analysis.
So inulin looks like a fibre with modest, measurable effects on glycaemia and bowel function, and no demonstrated effect on how long a mouse lives.
Mechanism of action
A polydisperse fructose polymer with a terminal glucose, linked beta-2,1 so that human digestive enzymes cannot cleave it. It passes intact to the colon where saccharolytic bacteria, notably Bifidobacterium, ferment it to short-chain fatty acids including acetate, propionate and butyrate. Butyrate is the preferred fuel of colonocytes; propionate reaches the liver and has been proposed to affect hepatic glucose output; and the fermentation shifts community composition, which is the prebiotic claim. It also increases stool water and bulk, which is the bowel-function claim. The same fermentation is why doses above roughly 10 to 15 g daily commonly cause bloating and flatulence.
Human evidence
A moderate randomised literature on glycaemic markers and bowel function, with nothing at all on lifespan, mortality or any ageing endpoint.
- Meta-analysis of 33 trials, 1,346 participants: HbA1c down 0.58 percentage points and fasting glucose down 0.60 mmol/L in prediabetes and type 2 diabetes, both graded high-quality evidence.
- Effects on fasting insulin and HOMA-IR were present but graded low quality.
- 12 g daily for four weeks improved stool frequency and constipation quality of life in 39 adults, with the trial's crossover design compromised by carry-over.
- The bifidogenic effect, meaning a rise in Bifidobacterium abundance, is the most consistently replicated finding in the human literature.
- Gastrointestinal intolerance, mainly bloating and flatulence, is common at the doses used in trials and is the usual reason people stop.
- No human study has examined lifespan, mortality or any geroscience endpoint.
What this does not tell you: HbA1c and stool frequency are useful outcomes but they are not longevity outcomes. Nothing in the human record tests whether inulin changes how long anyone lives or whether it delays any age-related disease. The one study that asked a lifespan question directly was in mice, and the answer was no.
Reading the research record
A lifespan null from this programme is a real, expensive, well-powered finding, and it is narrower than it sounds. What was tested was one concentration in the diet, started at one age, in one mouse strain, with death as the endpoint. A null tells you that this dose, in these animals, did not move that endpoint. It does not tell you the compound is inert, that a different dose would also fail, that the mechanism is wrong, or that the reason people actually take it has been refuted. Those are separate questions and most of them were never asked. The failure mode this site is trying to avoid runs in both directions: treating a mouse lifespan positive as proof that a supplement works, and treating a mouse lifespan null as proof that it does nothing.
Inulin is the gentlest illustration in this batch, and a useful one, because the comparison is built into a single paper. The same cohort, the same three sites, the same statistical machinery: glycine moved lifespan by 4 to 6 percent in both sexes and inulin moved it not at all. That is a clean within-experiment contrast, which is rarer than it sounds.
It also shows why the fibre-and-longevity argument needs care. Observational nutrition research consistently associates higher fibre intake with lower all-cause mortality, but whole-diet fibre intake and a purified fructan added to chow are not the same exposure. The ITP tested the second thing. The epidemiology is about the first, and it cannot separate fibre from everything else that travels with a high-fibre diet.
The Interventions Testing Program is funded by the National Institute on Aging and run in parallel at three independent laboratories, in Bar Harbor, Ann Arbor and San Antonio. It uses UM-HET3 mice, a four-way genetic cross, so no result can be an artefact of a single inbred background. Both sexes are studied, cohorts are sized to detect roughly a 10 percent shift in lifespan, compounds are fed in the diet from a stated starting age, and the programme commits in advance to publishing negative results alongside positive ones. That last commitment is why this batch can exist at all: almost no other part of ageing research reliably tells you what did not work.
The evidence, charted
Fig. 1 · evidence composition
1of 3 citations (33%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2019 and 2025.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2019
Glycine supplementation extends lifespan of male and female mice
Interventions Testing Program. An 8 percent glycine diet produced a 4 to 6 percent lifespan increase, with an increase in maximum lifespan, in both males (p equals 0.002) and females (p less than 0.001). In parallel analyses of the same cohort the authors report no benefit from TM5441, from inulin described as a source of soluble fibre, or from aspirin at either of two doses.
Aging Cell - Review2019
Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose-response meta-analysis of 33 randomized controlled trials
33 randomised trials, 1,346 participants. In prediabetes and type 2 diabetes, inulin-type fructans reduced fasting blood glucose by 0.60 mmol/L (95 percent CI -0.71 to -0.48, GRADE high) and HbA1c by 0.58 percentage points (95 percent CI -0.83 to -0.32, GRADE high), with smaller and lower-confidence reductions in fasting insulin and HOMA-IR. The dose-response analysis supported about 10 g daily for six weeks or longer.
Journal of Translational Medicine - Human2025
Inulin-induced improvements on bowel habit and gut microbiota in adults with functional constipation: findings of a randomized, double-blind, placebo-controlled study
39 adults with functional constipation, four weeks of 12 g chicory inulin daily in a double-blind placebo-controlled crossover. Stool frequency, abdominal symptoms and constipation-related quality of life improved relative to placebo, alongside higher relative abundance of butyrate-producing Anaerostipes and Coprococcus. A carry-over effect meant the crossover was compromised, and the authors re-analysed the first period alone as a parallel trial, which supported the same conclusion.
BMC Gastroenterology
Frequently asked questions
Does inulin help you live longer?
In mice it did not. The National Institute on Aging tested it in the same cohort where a glycine-enriched diet produced a 4 to 6 percent lifespan gain in both sexes, and inulin produced no benefit. No human study has looked at lifespan.
Does it actually lower blood sugar?
In people with prediabetes or type 2 diabetes, yes, modestly. Pooling 33 randomised trials, HbA1c fell by 0.58 percentage points and fasting glucose by 0.60 mmol/L, with the authors grading both as high-quality evidence. About 10 g daily for six weeks or more was the supported regimen.
How much causes gas?
Gastrointestinal intolerance rises with dose and is common at the 10 to 15 g range used in trials. It is the usual reason people stop taking it, and starting lower and building up is the standard advice.
Is inulin the same as taking a prebiotic?
Inulin is one of the best-studied prebiotics, and its most reproducible human effect is increasing Bifidobacterium abundance. Whether that shift produces any clinical benefit beyond the glycaemic and bowel outcomes above has not been established.